Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy

Pediatric Blood and Cancer

Volumn 50, Issue 3, 2008, Pages 627-629

  Dunn, Amy L ^a,b   Abshire, Thomas C ^a  

^a EMORY UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Central venous access device; Hemophilia; Infection; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CHILD; CLINICAL ARTICLE; GRAM POSITIVE BACTERIUM; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; DISEASE SUSCEPTIBILITY; DRUG EVALUATION; FACTOR VIII; FIBRIN; FIBRINOLYSIS; HEMOPHILIA A; HUMANS; ISOANTIBODIES; RECOMBINANT PROTEINS; THROMBOPHILIA; TISSUE PLASMINOGEN ACTIVATOR;

EID: 38549138337     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21095     Document Type: Article

References (20)

1. Berntorp E, Astermark J, Donfield SM, et al. Hemophilia inhibitor genetics study-evaluation of a model for studies of complex disease using linkage and association methods. Haemophilia 2005;11:427-429.
2. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-598.
3. Goodeve AC, Peake IR. The molecular basis of hemophilia A: Genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003;29:23-30.
4. Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucl Acids Res 1998;26:216-219.
5. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000;85:7-14.
6. Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIS Study Group. Blood 2003;102:2358-2363.
7. Bollard CM, Teague LR, Berry EW, et al. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000;6:66-70.
8. Ljung R, van den Berg M, Petrini P, et al. Port-a-cath usage in children with haemophilia: Experience of 53 cases. Acta Paediatr 1998;87:1051-1054.
9. Leisner RJ, Vora AJ, Hann IM, et al. Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol 1995;91:203-207.
10. Valentino LA, Ewenstein B, Navickis RJ, et al. Central venous access devices in haemophilia. Haemophilia 2004;10:134-146.
11. Journeycake JM, Quinn CT, Miller KL, et al. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001;98:1727-1731.
12. Price VE, Carcao M, Connolly B, et al. A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. J Thromb Haemost 2004;2:737-742.
13. Raad II, Luna M, Khalil S-A, et al. The relationship between the thrombotic and infectious complication of central venous catheters. JAMA 1994;271:1014-1016.
14. Timsit J-F, Farkas J-C, Boer J-M, et al. Central vein catheter-related thrombosis in intensive care patients: Incidence, risk factors, and relationship with catheter-related sepsis. Chest 1998;114:207-213.
15. Mehall JR, Saltzman DA, Jackson RJ, et al. Fibrin sheath enhances central venous catheter infection. Crit Care Med 2002;30:908-912.
16. Dillon PW, Jones GR, Bagnall-Reeb HA, et al. Prophylactic urokinase in the management of long-term venous access devices in children: A children's oncology group study. J Clin Oncol 2004;22:2718-2723.
17. Ray CE, Shenoy S, McCarthy PL. Weekly prophylactic urokinase installation in tunneled central venous access devices. J Vasc Interv Radiol 1999;10:1330-1334.
18. Cathflo™ Activase ® package insert Genentech Inc. 2005.
19. Fisher AA, Deffenbaugh C, Poole RL, et al. The use of alteplase for restoring patency to occluded central venous access devices in infants and children. J Infus Nurs 2004;27:171-174.
20. Semba CP, Deitcher SR, Li X, et al. Treatment of occluded central venous catheters with alteplase: Results in 1,064 patients. J Vasc Inter Radiol 2002;13:1199-1205.